Floatz logo

afm24

Colorectal Neoplasms

NKGen Biotech, Inc.Phase 1/2Active
D
26/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
11/ 100
Competitive Position
73/ 100

Competitive context

117 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

afm24 is also rated in:

refractory malignant neoplasmDormant
D
Indicative ·
26 / 100
View asset →
head and neck squamous cell carcinomaDormant
D
Indicative ·
26 / 100
View asset →
metastatic neoplasmDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →